Antiviral Chemotherapy 4

New Directions for Clinical Application and Research

  • John Mills
  • Paul A. Volberding
  • Lawrence Corey

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Gregory J. Mertz
    Pages 1-10
  3. Lawrence Corey, Anna Wald, L. Gray Davis
    Pages 11-16
  4. Ronald J. Boon, David R. J. Griffin
    Pages 17-31
  5. Richard Whitley, Ann M. Arvin, Stephen E. Straus, Richard B. Pollard, Gregory J. Mertz
    Pages 45-47
  6. Robin McKenzie, Stephen E. Straus
    Pages 67-83
  7. Stephen E. Follansbee, Mary Jean Stempien, William C. Buhles
    Pages 93-103
  8. Jacob P. Lalezari, Robert J. Stagg, Howard S. Jaffe, Michael J. M. Hitchcock, W. Lawrence Drew
    Pages 105-115
  9. Karen K. Biron
    Pages 135-143
  10. David P. Paar, Richard B. Pollard
    Pages 145-151
  11. Gregory Mertz, Louisa Chapman
    Pages 153-162
  12. Eurico Arruda, Frederick G. Hayden
    Pages 175-187
  13. Norah A. Terrault, Teresa L. Wright
    Pages 189-205
  14. David R. Gretch, Stephen J. Polyak, Richard A. Willson, Robert L. Carithers Jr.
    Pages 207-224
  15. Sven A. Danner
    Pages 225-243
  16. James Kahn
    Pages 245-256
  17. Gail Skowron
    Pages 257-269
  18. Gerald Friedland, Lisa W. Dunkle, Anne P. Cross
    Pages 271-277
  19. Andrew Carr, David A. Cooper
    Pages 299-304
  20. Keith Bragman
    Pages 305-317
  21. John M. Leonard
    Pages 319-325
  22. Emilio A. Emini, William A. Schleif, Paul Deutsch, Jon H. Condra
    Pages 327-331
  23. Ann C. Collier
    Pages 355-372
  24. James F. Rooney, John C. Warwick, Mary M. Elkins, Marty H. St. Clair, David W. Barry
    Pages 373-382
  25. Michael C. Sneller
    Pages 411-419
  26. Donald B. Kohn, Nava Sarver
    Pages 421-428
  27. Back Matter
    Pages 429-440

About this book


The three years since our last conference in San Francisco have again seen a dramatic expansion of the number of antivirals either licensed or in the late stages of clinical trials. d4T is now licensed for HIV infection, famciclovir and the oral pro-drug of acyclovir, valacyclovir, are now licensed for VZV infections in some countries. Moreover. oral ganciclovir, cidofovir, and sorivudine are not far behind. Clinical trials with the second-site reverse transcriptase inhibitors and the protease inhibitors for HlV infection are proceeding rapidly and on a broad scale, and the preliminary results would suggest that several of these classes of drugs will be licensed as well. Despite this optimism, however, there is increasing evidence that antiviral-resistant strains of pathogenic viruses will be a significant problem, perhaps especially with therapy of HIV infection, and there remains a desperate need for improved drugs (with either improved efficacy or decreased toxicity, or both) for CMV and HIV infections. This book is the edited proceedings of the Fourth Triennial Conference on Antiviral Chemotherapy, held in San Francisco, in November 1994. The conference was sponsored by the University of California, San Francisco, and co-sponsored by the International Society for Antiviral Research (ISAR), the Macfarlane Burnet Centre for Medical Research in Melbourne, Australia, and the Australian National Centre for HIV Virology Research. The conference had been organized to present an overview of the field of antiviral chemotherapy.


AIDS HIV chemotherapy clinical trial drugs genetics immunotherapy infection infections pharmacokinetics research resistance transplantation virology virus

Editors and affiliations

  • John Mills
    • 1
  • Paul A. Volberding
    • 2
  • Lawrence Corey
    • 3
  1. 1.Macfarlane Burnet Centre for Medical ResearchFairfieldAustralia
  2. 2.University of California San FranciscoSan FranciscoUSA
  3. 3.University of WashingtonSeattleUSA

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag US 1996
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4757-9211-9
  • Online ISBN 978-1-4757-9209-6
  • Series Print ISSN 0065-2598
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals